



## **Kala Pharmaceuticals to Report Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call**

March 19, 2018

WALTHAM, Mass.--(BUSINESS WIRE)--Mar. 19, 2018-- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a biopharmaceutical company focused on the development and commercialization of product candidates using its proprietary mucus-penetrating particle (MPP) technology, today announced that it will release fourth quarter and full year 2017 financial results on Monday, March 26, 2018. Kala will host a live conference call and webcast at 8:00 AM ET to provide a general business update and discuss the Company's 2017 financial results.

The dial-in numbers to access the conference call are 866-300-4091 for domestic callers and 703-736-7433 for international callers. The conference ID is 7082747. To access a live webcast and subsequent archived recording of the presentation, please visit "Events" in the "Investors" section of the Kala website at <http://kalarx.com/>.

### **About Kala Pharmaceuticals, Inc.**

Kala is a biopharmaceutical company focused on the development and commercialization of therapeutics using its proprietary mucus-penetrating particle (MPP) technology, with an initial focus on the treatment of eye diseases. Kala has applied the MPP technology to a corticosteroid designed for ocular applications, resulting in two lead product candidates. The product candidates are INVELTYS™ (KPI-121 1%) for the treatment of inflammation and pain following ocular surgery, for which an NDA has been accepted for review by the FDA, and KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20180319005365/en/>

Source: Kala Pharmaceuticals, Inc.

### **Investors and Media:**

MacDougall Biomedical Communications

Cammy Duong, 781-591-3443

[cduong@macbiocom.com](mailto:cduong@macbiocom.com)